A novel aromatase inhibitor, vorozole, shows antitumor activity and a decrease of tissue insulin-like growth factor-I level in 7, 12-dimethylbenz[a]anthracene-induced rat mammary tumors.

Abstract

Effects of vorozole, a potent and specific non-steroidal aromatase inhibitor, were evaluated on female Sprague-Dawley (SD) rats with 7, 12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors. Vorozole at a dose of 0.25, 1.0 and 4.0 mg/kg was orally administered once a day for 28 consecutive days. A significant regression in tumor size was observed in each treated group at 1, 2, 3 and 4 weeks after the start of treatment compared with control group. Tissue insulin-like growth factor I (IGF-I) in the DMBA-induced tumors in each treated group significantly decreased in a dose-dependent fashion compared with control group. These results show the mechanism of vorozole in DMBA-induced rat mammary tumors.

• Authors: N Sugamata, Y Koibuchi, Y Iino, Y Morishita
• Journal: International journal of oncology (Int J Oncol) Vol. 14 Issue 2 Pg. 259-63 (Feb 1999) ISSN: 1019-6439 [Print] Greece
• PMID: 9917500 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Aromatase Inhibitors
• Enzyme Inhibitors
• Triazoles
• vorozole
• 9,10-Dimethyl-1,2-benzanthracene
• Insulin-Like Growth Factor I

Topics

• 9,10-Dimethyl-1,2-benzanthracene
• Administration, Oral
• Animals
• Antineoplastic Agents (administration & dosage)
• Aromatase Inhibitors
• Enzyme Inhibitors (administration & dosage)
• Female
• Insulin-Like Growth Factor I (metabolism)
• Mammary Neoplasms, Experimental (chemically induced, drug therapy, metabolism)
• Rats
• Triazoles (administration & dosage)